The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Therapeutic strategies involving survivin inhibition in cancer
Open accessAbstract
Survivin is a small protein that belongs to the inhibitor of apoptosis protein family. It is abundantly expressed in tumors compared with adult differentiated tissues, being associated with poor prognosis in many human neoplasms. This apoptotic inhibitor has a relevant role in both the promotion of cancer cell survival and in the inhibition of cell death. Consequently, aberrant survivin expression stimulates tumor progression and confers resistance to several therapeutic strategies in a variety of tumors. In fact, efficient survivin downregulation or inhibition results in spontaneous apoptosis or sensitization to chemotherapy and radiotherapy. Therefore, all these features make survivin an attractive therapeutic target to treat cancer. Currently, there are several survivin inhibitors under clinical evaluation, although more specific and efficient survivin inhibitors are being developed. Moreover, novel combination regimens targeting survivin together with other therapeutic approaches are currently being designed and assessed. In this review, recent progress in the therapeutic options targeting survivin for cancer treatment is analyzed. Direct survivin inhibitors and their current development status are explored. Besides, the major signaling pathways implicated in survivin regulation are described and different therapeutic approaches involving survivin indirect inhibition are evaluated. Finally, promising novel inhibitors under preclinical or clinical evaluation as well as challenges of developing survivin inhibitors as a new therapy for cancer treatment are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family
Eckelman, B. P., Salvesen, G. S., & Scott, F. L. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400795 · Cited by 813
Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1752 · Cited by 563
Cited by
Maacha, S., Bhat, A. A., Jimenez, L., Raza, A., Haris, M., Uddin, S., & Grivel, J.-C. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0965-7 · Cited by 572
Nie, Y., Li, D., Peng, Y., Wang, S., Hu, S., Liu, M., Ding, J., & Zhou, W. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119513 · Cited by 495
Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting
Xu, M., Wang, Y., Xia, R., Wei, Y., & Wei, X. (2021) · Cell Proliferation · doi:10.1111/cpr.13115 · Cited by 382
Low temperature photothermal therapy: Advances and perspectives
Yang, K., Zhao, S., Li, B., Wang, B., Lan, M., & Song, X. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214330 · Cited by 309
Metadata
- Authors
- Martínez‐García, D., Manero‐Rupérez, N., Quesada, R., Korrodi‐Gregório, L., & Soto‐Cerrato, V.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2018-11-12
- Volume
- 39
- Issue
- 3
- Pages
- 887-909
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2901847905
- Cited by
- 166
- References
- 3
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic strategies involving survivin inhibition in cancer. https://app.cochat.ai/papers/10.1002/med.21547
- The paper
- Martínez‐García, D., Manero‐Rupérez, N., Quesada, R., Korrodi‐Gregório, L., & Soto‐Cerrato, V. (2019). Therapeutic strategies involving survivin inhibition in cancer. Medicinal Research Reviews. https://doi.org/10.1002/med.21547
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.